CervoMed Inc. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
CervoMed Inc. (CRVO) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $928.05 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2023-03-24
- CervoMed Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2022-12-31 was $189.91K.
- CervoMed Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2022-09-30 was $181.88K.
- CervoMed Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2022-06-30 was $278.13K.
- CervoMed Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2022-03-31 was $278.13K.
- CervoMed Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2022 was $928.05K.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2022-12-31 | $189.91K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $371.79K derived: sum of 2 quarters · filed 2023-03-24 | $649.92K derived: sum of 3 quarters · filed 2023-03-24 | $928.05K 10-K · filed 2023-03-24 |
| 2022-09-30 | $181.88K 10-Q · filed 2022-11-14 | $460.01K derived: sum of 2 quarters · filed 2022-11-14 | $738.14K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $278.13K 10-Q · filed 2022-08-12 | $556.26K 10-Q · filed 2022-08-12 | ||
| 2022-03-31 | $278.13K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |